← ResearchBird home
Oncology research, ranked for you
A PubMed alert for oncology that puts the studies most likely to matter first, with a one-line summary of each.
Start your free feedFree plan · no credit card
Oncology literature is split across tumour types, biomarkers, drug classes and supportive care, and every conference season adds more. A date-ordered PubMed alert buries the phase 3 trial under early-phase reports and retrospective series.
ResearchBird re-ranks each new study by importance, so trials, guidelines and meta-analyses come first. Each study is marked High, Medium or Low for your topic and gets a one-line summary, so a busy clinic day still leaves time to see what changed.
Create a feed for each tumour site or drug you follow and get a concise digest by email on your own schedule.
What a oncology digest looks like
Illustrative exampleTop 3 for you · re-ranked by importance
1
High
Adjuvant immunotherapy after resection of stage II to III colon cancer with mismatch repair deficiency
✦Longer disease-free survival, with manageable immune-related toxicity.
2
High
Circulating tumour DNA to guide adjuvant chemotherapy decisions
✦A positive result after surgery predicts relapse, but benefit from treatment is unproven.
3
Medium
Exercise programmes during chemotherapy and treatment completion
✦Higher completion rates among people in supervised programmes.